Management of Small Bowel Neuroendocrine Tumours: 10 Years' Experience at a Tertiary Referral Centre.
multimodal treatment
neuroendocrine
small intestine
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
25
07
2023
revised:
24
08
2023
accepted:
01
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Neuroendocrine tumours (NET) arising from the small bowel are clinically challenging and are often diagnosed at advanced stages. Disease control with surgery alone can be demanding. Multimodal treatment concepts integrating surgery and non-surgical modalities could be of benefit. Retrospective review of consecutive adult patients with SB NET treated at Imperial College Healthcare NHS Trust between 1 January 2010 and 31 December 2019. Data regarding clinicopathological characteristics, treatments, and disease trajectory were extracted and summarised. Overall and progression/recurrence-free survival were estimated at 5 and 10 years. 154 patients were identified, with a median age of 64 years (range 33-87); 135/154 (87.7%) had stage III/IV disease at diagnosis. Surgery was used in 125 individuals (81.2%), typically with either segmental small bowel resection (60.8%) or right hemicolectomy (33.6%) and mesenteric lymphadenectomy for the primary tumour. Systemic and/or liver-directed therapies were used in 126 (81.8%); 60 (47.6%) had more than one line of non-surgical treatment. Median follow-up was 67.2 months (range 3.1-310.4); overall survival at 5 and 10 years was 91.0% (95% CI: 84.9-94.7%) and 82.5% (95% CI: 72.9-88.9%), respectively. Imaging-based median progression-free survival was 42.7 months (95% CI: 24.7 to 72.4); 5-year progression-free survival was 63.4% (95% CI: 55.0-70.6%); 10-year progression-free survival was 18.7% (95% CI: 12.4-26.1). Nineteen patients (12.3%) reached 10 years follow-up without disease recurrence and therefore were considered cured. Most patients with SB NET present in a metastasised stage. Multimodal treatment concepts may be associated with excellent clinical outcomes. Future work should explore optimal approaches to treatment sequencing and patient selection.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine tumours (NET) arising from the small bowel are clinically challenging and are often diagnosed at advanced stages. Disease control with surgery alone can be demanding. Multimodal treatment concepts integrating surgery and non-surgical modalities could be of benefit.
METHOD
METHODS
Retrospective review of consecutive adult patients with SB NET treated at Imperial College Healthcare NHS Trust between 1 January 2010 and 31 December 2019. Data regarding clinicopathological characteristics, treatments, and disease trajectory were extracted and summarised. Overall and progression/recurrence-free survival were estimated at 5 and 10 years.
RESULTS
RESULTS
154 patients were identified, with a median age of 64 years (range 33-87); 135/154 (87.7%) had stage III/IV disease at diagnosis. Surgery was used in 125 individuals (81.2%), typically with either segmental small bowel resection (60.8%) or right hemicolectomy (33.6%) and mesenteric lymphadenectomy for the primary tumour. Systemic and/or liver-directed therapies were used in 126 (81.8%); 60 (47.6%) had more than one line of non-surgical treatment. Median follow-up was 67.2 months (range 3.1-310.4); overall survival at 5 and 10 years was 91.0% (95% CI: 84.9-94.7%) and 82.5% (95% CI: 72.9-88.9%), respectively. Imaging-based median progression-free survival was 42.7 months (95% CI: 24.7 to 72.4); 5-year progression-free survival was 63.4% (95% CI: 55.0-70.6%); 10-year progression-free survival was 18.7% (95% CI: 12.4-26.1). Nineteen patients (12.3%) reached 10 years follow-up without disease recurrence and therefore were considered cured.
CONCLUSIONS
CONCLUSIONS
Most patients with SB NET present in a metastasised stage. Multimodal treatment concepts may be associated with excellent clinical outcomes. Future work should explore optimal approaches to treatment sequencing and patient selection.
Identifiants
pubmed: 37760408
pii: cancers15184438
doi: 10.3390/cancers15184438
pmc: PMC10526159
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Heinz Horst Deichmann Foundation
ID : HHDF1
Organisme : European Union FP7
ID : PD
Références
World J Surg. 2000 Nov;24(11):1402-8
pubmed: 11038214
BMC Genomics. 2014 Jul 15;15:595
pubmed: 25023465
HPB (Oxford). 2019 Jul;21(7):773-783
pubmed: 30733049
J Am Coll Surg. 2003 Jul;197(1):29-37
pubmed: 12831921
Ann Surg. 2021 Jul 1;274(1):e1-e9
pubmed: 31373926
Endocr Connect. 2018 Dec;7(12):1245-1250
pubmed: 30352418
Surg Endosc. 2014 May;28(5):1720-6
pubmed: 24380996
Surgery. 2018 Apr;163(4):761-767
pubmed: 29284590
Nat Commun. 2021 Nov 4;12(1):6367
pubmed: 34737276
JAMA Surg. 2019 Feb 1;154(2):134-140
pubmed: 30383112
J Gastrointest Surg. 2016 Jan;20(1):180-8; discussion 188
pubmed: 26394880
HPB (Oxford). 2010 Aug;12(6):427-33
pubmed: 20662794
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Surgery. 2019 Jan;165(1):166-175
pubmed: 30343949
JAMA Oncol. 2018 Feb 01;4(2):183-189
pubmed: 29049611
BMC Med Res Methodol. 2020 Mar 26;20(1):71
pubmed: 32216765
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
Ann Surg. 2010 Nov;252(5):850-6
pubmed: 21037441
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
J Surg Oncol. 2017 Sep;116(3):298-306
pubmed: 28513896
Cancer. 1997 Feb 15;79(4):813-29
pubmed: 9024720
J Oncol. 2018 Nov 14;2018:6273947
pubmed: 30538745
J Nucl Med. 2021 Nov;62(11):1558-1563
pubmed: 33637590
Surgery. 2014 Dec;156(6):1369-76; discussion 1376-7
pubmed: 25456912
World J Surg. 2021 Jan;45(1):197-202
pubmed: 32737557
Surg Endosc. 2013 Oct;27(10):3678-82
pubmed: 23572224
World J Surg. 2012 Jun;36(6):1419-31
pubmed: 21984144
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Arch Pathol Lab Med. 1990 Jul;114(7):700-4
pubmed: 1694655
Ann Surg. 2021 Sep 1;274(3):481-490
pubmed: 34183517
J Hepatobiliary Pancreat Surg. 2005;12(5):351-5
pubmed: 16258801
Am J Surg Pathol. 2017 Jan;41(1):128-133
pubmed: 27684993
J Gastrointest Surg. 2020 Jul;24(7):1530-1539
pubmed: 31346887
Dis Colon Rectum. 2021 Oct 1;64(10):1240-1248
pubmed: 33661232
Lancet Oncol. 2021 Dec;22(12):1752-1763
pubmed: 34793718
Surgery. 2021 Jan;169(1):168-174
pubmed: 32473829
Surgery. 2017 Jan;161(1):272-279
pubmed: 27863780
Ann Endocrinol (Paris). 2019 Jun;80(3):153-158
pubmed: 31072588
Clin Cancer Res. 2016 Jan 1;22(1):250-8
pubmed: 26169971
World J Surg. 2020 Jul;44(7):2377-2384
pubmed: 32179974
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S742-9
pubmed: 26014153
World J Surg. 2021 Aug;45(8):2482-2491
pubmed: 33895862
Ann Surg Oncol. 2010 Dec;17(12):3129-36
pubmed: 20585879
World J Surg. 2021 Jan;45(1):213-218
pubmed: 32797281
J Gastrointest Oncol. 2019 Oct;10(5):869-877
pubmed: 31602324
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Surg Oncol. 2020 Aug;122(2):204-211
pubmed: 32291778
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Virchows Arch. 2007 Oct;451(4):757-62
pubmed: 17674042
Innov Surg Sci. 2017 Aug 25;2(4):247-253
pubmed: 31579758
Pancreas. 2017 Oct;46(9):1115-1120
pubmed: 28902780
Neuroendocrinology. 2016;103(5):552-9
pubmed: 26445315
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Br J Surg. 2022 Feb 1;109(2):191-199
pubmed: 34941998
J Gastrointest Surg. 2018 Feb;22(2):303-309
pubmed: 29119527
Int J Med Sci. 2021 Mar 19;18(10):2166-2175
pubmed: 33859524
J Gastrointest Surg. 2018 Jan;22(1):117-123
pubmed: 28819895
Ann Surg Oncol. 2017 Aug;24(8):2319-2325
pubmed: 28303430
Endocr Relat Cancer. 2009 Sep;16(3):885-94
pubmed: 19458024
Surg Today. 2013 Oct;43(10):1168-74
pubmed: 23143168
Ann Surg Oncol. 2016 Dec;23(Suppl 5):804-808
pubmed: 27613554
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Neuroendocrinol. 2022 Jun;34(6):e13117
pubmed: 35434838
HPB (Oxford). 2020 Apr;22(4):537-544
pubmed: 31540885
World J Surg. 2014 Jun;38(6):1353-61
pubmed: 24493070
Surg Oncol. 2012 Sep;21(3):e131-41
pubmed: 22658833
J Am Coll Surg. 2014 Apr;218(4):837-44
pubmed: 24655881
Ann Surg. 2021 Jul 1;274(1):e45-e53
pubmed: 33030849
Endocr Relat Cancer. 2009 Sep;16(3):977-90
pubmed: 19470616
Br J Surg. 2009 Feb;96(2):175-84
pubmed: 19160361
Surgery. 2016 Jan;159(1):320-33
pubmed: 26454679
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Endocr Relat Cancer. 2022 Feb 07;29(3):163-173
pubmed: 34982042
Ann Surg. 2022 Nov 1;276(5):e450-e458
pubmed: 33214481
Neuroendocrinology. 2020;110(6):444-476
pubmed: 31557758
Oncotarget. 2017 Jan 17;8(3):4935-4947
pubmed: 27903960